Paul F Torrence

US Patent:

20030203356, Oct 30, 2003

Filed:

Jan 22, 2003

Appl. No.:

10/349163

Inventors:

Robert Silverman - Beachwood OH, US
Hagen Cramer - Cleveland Heights OH, US
Douglas Leaman - Whitehouse OH, US
Paul Torrence - Flagstaff AZ, US

Assignee:

The Cleveland Clinic Foundation - Cleveland OH

International Classification:

A61K048/00
C07H021/02
C12Q001/70

US Classification:

435/005000, 536/023720, 514/044000

Abstract:

The present invention relates to methods of targeting RNA and is particularly useful for inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a target RNA (e.g. a negative strand RNA virus) to specifically cleave the genomic or antigenomic RNA strand of the target RNA (e.g. the virus). The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an “antisense oligonucleotide”) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.

US Patent:

62713698, Aug 7, 2001

Filed:

Oct 14, 1997

Appl. No.:

8/950196

Inventors:

Paul F. Torrence - Flagstaff AZ
Robert H. Silverman - Beechwood OH
Ratan K. Maitra - South Euclid OH
Krystyna Lesiak - Stone Mountain GA

Assignee:

The United States of America as represented by the Department of Health and
Human Services - Washington DC
The Cleveland Clinic Foundation - Cleveland OH

International Classification:

C07H 2102
C07H 2104
C12Q 168

US Classification:

536 245

Abstract:

Chimeric molecules comprising a virus targeting antisense oligonucleotide moiety attached to an activator of 2-5A-dependent RNase.